Lorusso Roberto, Gelsomino Sandro, Parise Orlando, Mendiratta Priya, Prodhan Parthak, Rycus Peter, MacLaren Graeme, Brogan Thomas V, Chen Yih-Sharng, Maessen Jos, Hou Xiaotong, Thiagarajan Ravi R
Cardio-Thoracic Surgery Unit, Maastricht University Medical Centre, Maastricht, The Netherlands.
Cardio-Thoracic Surgery Unit, Maastricht University Medical Centre, Maastricht, The Netherlands.
Ann Thorac Surg. 2017 Jul;104(1):62-69. doi: 10.1016/j.athoracsur.2016.10.023. Epub 2017 Jan 26.
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock (RCS) is increasingly used in adult patients, but age represents a controversial factor in this setting.
Data from the Extracorporeal Life Support Organization registry was analyzed to assess in-hospital survival of elderly patients (≥70 years of age) undergoing VA-ECMO for RCS from 1992 to 2015. In-hospital survival and complications for elderly patients were compared with data in younger adults (≥18 to <70 years of age) supported with VA-ECMO during the same time period for similar indications.
The mean age of the patient cohort (n = 5,408) was 53.0 ± 15.7 years (range, 18 to 91 years). The elderly group included 735 patients (13.6%), with a mean age of 75.2 ± 4.4 years. In the elderly group, pre-ECMO cardiac procedures were performed in 134 cases (18.9%), and 2.2% received VA-ECMO for postcardiotomy support compared with 0.7% in the younger cohort. The mean duration of VA-ECMO in the elderly group was 101 ± 91 h compared with 138 ± 146 h in the younger group (p < 0.001). Overall, survival to hospital discharge for the entire adult cohort was 41.4% (2,240 of 5,408), with 30.5% (224 of 735) in the elderly patient group and 43.1% (2,016 of 4,673) in the younger patient group (p < 0.001). Elderly patients had a higher rate of multiorgan failure. At multivariable analysis age represented an independent negative predictor of in-hospital survival.
Based on the acceptable survival to hospital discharge in our study, older age alone should not represent an absolute contraindication when considering VA-ECMO support for RCS.
静脉-动脉体外膜肺氧合(VA-ECMO)用于治疗难治性心源性休克(RCS)在成年患者中越来越常用,但在这种情况下年龄是一个有争议的因素。
分析体外生命支持组织登记处的数据,以评估1992年至2015年接受VA-ECMO治疗RCS的老年患者(≥70岁)的院内生存率。将老年患者的院内生存率和并发症与同期因类似适应症接受VA-ECMO支持的年轻成年人(≥18至<70岁)的数据进行比较。
患者队列(n = 5408)的平均年龄为53.0±15.7岁(范围18至91岁)。老年组包括735例患者(13.6%),平均年龄为75.2±4.4岁。在老年组中,134例(18.9%)在ECMO前进行了心脏手术,2.2%接受VA-ECMO用于心脏术后支持,而年轻队列中这一比例为0.7%。老年组VA-ECMO的平均持续时间为101±91小时,而年轻组为138±146小时(p<0.001)。总体而言,整个成年队列的出院生存率为41.4%(5408例中的2240例),老年患者组为30.5%(735例中的224例),年轻患者组为43.1%(4673例中的2016例)(p<0.001)。老年患者多器官衰竭的发生率更高。在多变量分析中,年龄是院内生存的独立负性预测因素。
基于我们研究中可接受出院生存率,在考虑对RCS患者进行VA-ECMO支持时,仅年龄不应成为绝对禁忌证。